In vitro susceptibility testing in fungi: What is its role in clinical practice?

Current Infectious Disease Reports

Volumn 12, Issue 6, 2010, Pages 401-408

  Perkhofer, Susanne ^a   Mrazek, Cornelia ^a   Hartl, Lukas ^b   Lass Flörl, Cornelia ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INSTITUT PASTEUR   (France)

Author keywords

Amphotericin B; Aspergillus spp in vitro susceptibility testing; Candida spp; Caspofungin; Combination testing; Etest; Microdilution; Minimal fungicidal concentration; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; IMIDAZOLE DERIVATIVE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; VORICONAZOLE;

AGAR DIFFUSION; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; CHEMOTHERAPY; CLINICAL PRACTICE; DISK DIFFUSION; DRUG EXPOSURE; EPSILOMETER TEST; ESOPHAGUS CANDIDIASIS; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MOULD; MUCORMYCOSIS; NONHUMAN; REVIEW; SYSTEMIC MYCOSIS; TRANSPLANTATION; YEAST;

EID: 77958179496     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-010-0134-z     Document Type: Review

References (50)

1. RG Holzheimer H Dralle 2002 Management of mycoses in surgical patients: review of the literature Eur J Med Res 7 200 226 12069912
2. Ito JI, Kriengkauykiat J, Dadwal SS, et al.: Approaches to the early treatment of invasive fungal infection. Leuk Lymphoma 2010 (Epub ahead of print).
3. C Lass-Flörl 2009 The changing face of epidemiology of invasive fungal disease in Europe Mycoses 52 197 205 10.1111/j.1439-0507.2009.01691.x 19391253 This review describes the changes of epidemiology of invasive fungal infections. This knowledge is an important factor that must be considered in the decision for the appropriate antifungal agent
4. M Cuenca-Estrella JL Rodriguez-Tudela 2010 The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro Expert Rev Anti Infect Ther 8 267 276 1:CAS:528:DC%2BC3cXis1eht7Y%3D 10.1586/eri.10.2 20192681
5. CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard-Second Edition. CLSI document M38-A2. Wayne PA: Clinical and Laboratory Standards Institute; 2008.
6. CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Third Edition. CLSI document M27-A3. Wayne PA: Clinical and Laboratory Standards Institute; 2008.
7. EUCAST technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin Microbiol Infect 2008, 14:982-984.
8. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin Microbiol Infect 2008, 14:398-405.
9. C Lass-Flörl K Griff A Mayr, et al. 2005 Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience Br J Haematol 131 201 207 10.1111/j.1365-2141.2005.05763.x 16197450 (Pubitemid 43899686)
10. CLSI Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Third Informational Supplement. CLSI document M27-S3. Wayne PA: Clinical and Laboratory Standards Institute; 2008.
11. MA Pfaller DJ Diekema JH Rex, et al. 2006 Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints J Clin Microbiol 44 819 826 1:STN:280: DC%2BD287ivFOmtQ%3D%3D 10.1128/JCM.44.3.819-826.2006 16517860
12. EUCAST technical note on fluconazole. Clin Microbiol Infect 2008, 14:193-195.
13. EUCAST technical note on voriconazole. Clin Microbiol Infect 2008, 14:985-987.
14. A Aberkane M Cuenca-Estrella A Gomez-Lopez, et al. 2002 Comparative evaluation of two different methods of inoculum preparation for antifungal susceptibility testing of filamentous fungi J Antimicrob Chemother 50 719 722 1:CAS:528:DC%2BD38XosVSrurY%3D 10.1093/jac/dkf187 12407129
15. M Cuenca-Estrella MC Arendrup E Chryssanthou, et al. 2007 Multicentre determination of quality control strains and quality control ranges for antifungal susceptibility testing of yeasts and filamentous fungi using the methods of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST) Clin Microbiol Infect 13 1018 1022 1:STN:280:DC%2BD2snksVGgsA%3D%3D 10.1111/j.1469-0691.2007. 01790.x 17697001 (Pubitemid 47382259)
16. A Espinel-Ingroff F Barchiesi M Cuenca-Estrella, et al. 2005 International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole J Clin Microbiol 43 3884 3889 1:CAS:528:DC%2BD2MXpvVCrurw%3D 10.1128/JCM.43.8.3884-3889.2005 16081926 (Pubitemid 41129676)
17. E Chryssanthou M Cuenca-Estrella 2006 Comparison of the EUCAST-AFST broth dilution method with the CLSI reference broth dilution method (M38-A) for susceptibility testing of posaconazole and voriconazole against Aspergillus spp Clin Microbiol Infect 12 901 904 1:CAS:528:DC%2BD28XhtVeht7fL 10.1111/j.1469-0691.2006.01419.x 16882296 (Pubitemid 44151291)
18. MA Pfaller M Castanheira DJ Diekema, et al. 2010 Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and Etest methods with the CLSI broth microdilution method for echinocandin susceptibility testing of Candida species J Clin Microbiol 48 1592 1599 1:CAS:528:DC%2BC3cXnt1Cgur8%3D 10.1128/JCM.02445-09 20335424
19. S Perkhofer D Jost MP Dierich, et al. 2008 Susceptibility testing of anidulafungin and voriconazole alone and in combination against conidia and hyphae of Aspergillus spp. under hypoxic conditions Antimicrob Agents Chemother 52 1873 1875 1:CAS:528:DC%2BD1cXls1ais7w%3D 10.1128/AAC.01572-07 18347112 (Pubitemid 351614693)
20. J Fuller A Schofield S Jiwa, et al. 2010 Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration J Clin Microbiol 48 479 482 1:CAS:528:DC%2BC3cXkt1SjtLo%3D 10.1128/JCM.01677-09 20007389
21. M Negri M Henriques TI Svidzinski, et al. 2009 Correlation between Etest, disk diffusion, and microdilution methods for antifungal susceptibility testing of Candida species from infection and colonization J Clin Lab Anal 23 324 330 10.1002/jcla.20337 19785043
22. CLSI Methods for Antifungal Disk Diffusion Susceptibility Testing of Yeasts; Approved Standard M44-A. Wayne PA: Clinical and Laboratory Standards Institute; 2004.
23. MA Pfaller KC Hazen SA Messer, et al. 2004 Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program J Clin Microbiol 42 3607 3612 1:CAS:528:DC%2BD2cXnt1OgtL8%3D 10.1128/JCM.42.8.3607-3612.2004 15297505 (Pubitemid 39045688)
24. A Espinel-Ingroff B Arthington-Skaggs N Iqbal, et al. 2007 Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin J Clin Microbiol 45 1811 1820 1:CAS:528:DC%2BD2sXnsVKru78%3D 10.1128/JCM.00134-07 17428932 (Pubitemid 46933912)
25. MA Pfaller V Chaturvedi DJ Diekema, et al. 2008 Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin J Clin Microbiol 46 2155 2159 1:CAS:528:DC%2BD1cXps1OnurY%3D 10.1128/JCM.00493-08 18463213
26. C Castro MC Serrano B Flores, et al. 2004 Comparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38: a method to determine the activity of voriconazole against clinical isolates of Aspergillus spp J Clin Microbiol 42 4358 4360 1:CAS:528:DC%2BD2cXosVyhsLk%3D 10.1128/JCM.42.9.4358-4360.2004 15365044 (Pubitemid 39296177)
27. JM Torres-Rodriguez E Alvarado-Ramirez 2007 In vitro susceptibilities to yeasts using the ATB FUNGUS 2 method, compared with Sensititre Yeast One and standard CLSI (NCCLS) M27-A2 methods J Antimicrob Chemother 60 658 661 1:CAS:528:DC%2BD2sXpt1CmtL0%3D 10.1093/jac/dkm247 17623690 (Pubitemid 47299885)
28. M Avolio S Grosso G Bruschetta, et al. 2009 Direct antifungal susceptibility testing of positive Candida blood cultures by sensititre YeastOne New Microbiol 32 179 184 1:CAS:528:DC%2BD1MXotFShu7k%3D 19579696
29. MA Pfaller DJ Diekema GW Procop, et al. 2007 Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp J Clin Microbiol 45 3522 3528 1:CAS:528:DC%2BD2sXhsVWrtLrM 10.1128/JCM.00403-07 17913927 (Pubitemid 350156842)
30. B Jahn A Stuben S Bhakdi 1996 Colorimetric susceptibility testing for Aspergillus fumigatus: comparison of menadione-augmented 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide and Alamar blue tests J Clin Microbiol 34 2039 2041 1:CAS:528:DyaK28XkvFShs74%3D 8818910
31. R Ramani V Chaturvedi 2000 Flow cytometry antifungal susceptibility testing of pathogenic yeasts other than Candida albicans and comparison with the NCCLS broth microdilution test Antimicrob Agents Chemother 44 2752 2758 1:CAS:528:DC%2BD3cXmvVyqt7o%3D 10.1128/AAC.44.10.2752-2758.2000 10991856
32. R Ramani M Gangwar V Chaturvedi 2003 Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-a-vis amphotericin B and itraconazole Antimicrob Agents Chemother 47 3627 3629 1:CAS:528:DC%2BD3sXovVaiur4%3D 10.1128/AAC.47.11.3627- 3629.2003 14576132 (Pubitemid 37345734)
33. CH Klaassen HA de Valk IM Curfs-Breuker, et al. 2010 Novel mixed-format real-time PCR assay to detect mutations conferring resistance to triazoles in Aspergillus fumigatus and prevalence of multi-triazole resistance among clinical isolates in the Netherlands J Antimicrob Chemother 65 901 905 1:CAS:528:DC%2BC3cXks1Gmsr0%3D 10.1093/jac/dkq041 20167588
34. C Marinach A Alanio M Palous, et al. 2009 MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole Proteomics 9 4627 4631 1:CAS:528:DC%2BD1MXht1Ort7vO 10.1002/pmic.200900152 19750514
35. J Meletiadis S Pournaras E Roilides, et al. 2010 Defining fractional inhibitory concentration index cutoffs for additive interactions based on self-drug additive combinations, Monte Carlo simulation analysis, and in vitro-in vivo correlation data for antifungal drug combinations against Aspergillus fumigatus Antimicrob Agents Chemother 54 602 609 1:CAS:528:DC%2BC3cXhvFSitLY%3D 10.1128/AAC.00999-09 19995928
36. MD Johnson C MacDougall L Ostrosky-Zeichner, et al. 2004 Combination antifungal therapy Antimicrob Agents Chemother 48 693 715 1:CAS:528: DC%2BD2cXitVGhsLk%3D 10.1128/AAC.48.3.693-715.2004 14982754 (Pubitemid 38280314)
37. A Espinel-Ingroff A Fothergill J Peter, et al. 2002 Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study J Clin Microbiol 40 3204 3208 1:CAS:528:DC%2BD38XnsVClsbs%3D 10.1128/JCM.40.9.3204- 3208.2002 12202554 (Pubitemid 34977429)
38. A Warris CM Weemaes PE Verweij 2002 Multidrug resistance in Aspergillus fumigatus N Engl J Med 347 2173 2174 10.1056/NEJM200212263472618 12501236
39. MY Moosa GJ Alangaden E Manavathu, et al. 2002 Resistance to amphotericin B does not emerge during treatment for invasive aspergillosis J Antimicrob Chemother 49 209 213 1:CAS:528:DC%2BD38Xosl2gtQ%3D%3D 10.1093/jac/49.1.209 11751792
40. S Walmsley S King A McGeer, et al. 2001 Oropharyngeal candidiasis in patients with human immunodeficiency virus: correlation of clinical outcome with in vitro resistance, serum azole levels, and immunosuppression Clin Infect Dis 32 1554 1561 1:CAS:528:DC%2BD3MXksVyitL4%3D 10.1086/320517 11340526 (Pubitemid 32458722)
41. S Hernandez JL Lopez-Ribot LK Najvar, et al. 2004 Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis Antimicrob Agents Chemother 48 1382 1383 1:CAS:528:DC%2BD2cXjtVKqsLg%3D 10.1128/AAC.48.4.1382-1383.2004 15047549 (Pubitemid 38405501)
42. M Marine C Serena B Fernandez-Torres, et al. 2005 Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata Antimicrob Agents Chemother 49 4757 4759 1:CAS:528:DC%2BD2MXht1Siu7rK 10.1128/AAC.49.11.4757-4759.2005 16251323 (Pubitemid 41552611)
43. N Kartsonis J Killar L Mixson, et al. 2005 Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome Antimicrob Agents Chemother 49 3616 3623 1:CAS:528:DC%2BD2MXpvFKlt7g%3D 10.1128/AAC.49.9.3616- 3623.2005 16127030 (Pubitemid 41233008)
44. SH Alves E Boff P Pozzatti, et al. 2009 Relationship between susceptibility of Candida spp. isolates to amphotericin B and death or survival of patients with candidemia episodes Mycopathologia 167 65 71 10.1007/s11046-008-9159-3 18819017 This study demonstrates that the choice of culture media is critical for antifungal susceptibility testing of amphotericin B
45. MC Arendrup S Perkhofer SJ Howard, et al. 2008 Establishing in vitro-in vivo correlations for Aspergillus fumigatus: the challenge of azoles versus echinocandins Antimicrob Agents Chemother 52 3504 3511 1:CAS:528: DC%2BD1cXht1SrtbjJ 10.1128/AAC.00190-08 18644959 This study describes and confirms in an animal model a clinical A. fumigatus isolate with significantly decreased caspofungin susceptibility and a clinical isolate from Denmark with multi-azole resistance. Furthermore, these data identify the growing problem of lack of susceptibility among clinical A. fumigatus isolates and the need for monitoring susceptibility
46. MM Rodriguez FJ Pastor E Calvo, et al. 2009 Correlation of in vitro activity, serum levels, and in vivo efficacy of posaconazole against Rhizopus microsporus in a murine disseminated infection Antimicrob Agents Chemother 53 5022 5025 1:CAS:528:DC%2BD1MXhsF2gs7jO 10.1128/AAC.01026-09 19786601
47. E Dannaoui JF Meis D Loebenberg, et al. 2003 Activity of posaconazole in treatment of experimental disseminated zygomycosis Antimicrob Agents Chemother 47 3647 3650 1:CAS:528:DC%2BD3sXovVaiurg%3D 10.1128/AAC.47.11.3647-3650.2003 14576138 (Pubitemid 37345740)
48. TC White KA Marr RA Bowden 1998 Clinical, cellular, and molecular factors that contribute to antifungal drug resistance Clin Microbiol Rev 11 382 402 1:CAS:528:DyaK1cXislers7w%3D 9564569
49. JH Rex MA Pfaller 2002 Has antifungal susceptibility testing come of age? Clin Infect Dis 35 982 989 1:CAS:528:DC%2BD38XoslOmurw%3D 10.1086/342384 12355386 (Pubitemid 35178316)
50. E Johnson A Espinel-Ingroff A Szekely, et al. 2008 Activity of voriconazole, itraconazole, fluconazole and amphotericin B in vitro against 1763 yeasts from 472 patients in the voriconazole phase III clinical studies Int J Antimicrob Agents 32 511 514 1:CAS:528:DC%2BD1cXhtlGls7zM 10.1016/j.ijantimicag. 2008.05.023 18790613